SCHEDULE 13G/A: ARK Investment Management Discloses 9.15% Stake in Twist Bioscience Corp

ARK Investment Management LLC has filed an amended Schedule 13G, revealing a beneficial ownership of 9.15% of Twist Bioscience Corp's common stock as of September 30, 2024.

Summary

• ARK Investment Management LLC, an investment adviser based in Delaware, reported beneficial ownership of 5,358,093 shares of Twist Bioscience Corp's common stock.
• This ownership represents 9.15% of the total outstanding common stock of Twist Bioscience Corp.
• ARK Investment Management holds sole voting power over 5,143,317 shares and shared voting power over 86,252 shares.
• The firm also holds sole dispositive power over 5,358,093 shares and no shared dispositive power.
• The filing is an Amendment No. 5, indicating previous ownership disclosures by ARK Investment Management regarding Twist Bioscience Corp.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to a significant stake being held by a reputable investment firm, which can be interpreted as a vote of confidence. However, as a purely factual ownership disclosure, it lacks explicit positive or negative performance data.

Positives

• The disclosure of a significant 9.15% stake by a prominent investment firm like ARK Investment Management may signal strong investor confidence in Twist Bioscience Corp's long-term prospects.
• The statement that shares are held in the ordinary course of business suggests a strategic, non-activist investment approach.

Future Outlook

This document does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.

Industry Context

This filing reflects a significant investment by a major asset manager in a biotechnology company, indicating continued institutional interest in the synthetic biology and genomics sectors. While not providing industry trends, it highlights a specific firm's conviction in a player within this innovative space.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding by ARK Investment Management may influence investor perception and potentially the stock price, signaling institutional confidence.
• Company Management: Awareness of a large, non-activist institutional holder like ARK may influence strategic decisions, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Twist Bioscience Corp, ARK Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Biotechnology, Synthetic Biology